Freestone Grove Partners LP Purchases Shares of 11,141 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Freestone Grove Partners LP acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,141 shares of the specialty pharmaceutical company's stock, valued at approximately $319,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after acquiring an additional 316 shares during the period. AlphaQuest LLC increased its stake in shares of Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after purchasing an additional 374 shares in the last quarter. Foundry Partners LLC grew its holdings in Collegium Pharmaceutical by 2.4% during the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company's stock valued at $463,000 after purchasing an additional 381 shares during the period. Gallacher Capital Management LLC lifted its position in shares of Collegium Pharmaceutical by 3.3% during the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company's stock valued at $417,000 after buying an additional 470 shares in the last quarter. Finally, Caprock Group LLC grew its stake in shares of Collegium Pharmaceutical by 6.7% during the 4th quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock valued at $249,000 after acquiring an additional 543 shares during the period.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 1,949 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the transaction, the chief financial officer now directly owns 177,195 shares in the company, valued at approximately $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares of the company's stock, valued at $4,330,048.32. The trade was a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock valued at $2,334,994 in the last quarter. 2.51% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on COLL. Needham & Company LLC restated a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler lowered their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. StockNews.com downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $43.60.

Collegium Pharmaceutical Trading Up 0.1 %

Shares of Collegium Pharmaceutical stock traded up $0.02 on Wednesday, reaching $27.05. The company had a trading volume of 301,319 shares, compared to its average volume of 442,255. The firm has a market cap of $869.17 million, a price-to-earnings ratio of 11.66 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm's 50-day moving average price is $28.15 and its two-hundred day moving average price is $30.21. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.